TRUST EARNED THROUGH PROOF, NOT PROMISES.
Sponsors choose Biorasi for a proven record of delivering exactly what’s promised — with transparency, integrity, and precision at every stage of the trial.
WHY BIORASI?

Reliability
Over 200 global studies executed, 5 FDA approvals in the past seven years, and a track record of delivering even in the most challenging scenarios.
Flexibility
Customizable operating models that scale to each trial, from first-in-human to global Phase III, without the bureaucracy that slows larger CROs.
Accessibility
Direct access to decision-makers, senior scientists, and real-time performance dashboards — no layers, no guesswork.
THE BIORASI ADVANTAGE
COMPETITIVE EDGE
OVER LARGER CROS
- Leaner governance means faster pivots when protocols change or challenges arise.
- Embedded “One Team” approach keeps decision-makers close to your study, not insulated by account layers.
- Proven rescue expertise across $150M+ in recovered studies.
STANDING OUT
OVER NICHE CROs
- Global site network across 48 countries, with AI-enhanced feasibility solutions..
- Full-service capabilities — clinical operations, data sciences, medical affairs, and regulatory compliance — all under one coordinated team.
- Specialized experience in innovative therapeutic areas: Dermatology, Oncology, Neurology, Nephrology, and Cell Therapy.
PROOF OF
PERFORMANCE
- 200+ global studies executed
- FDA approvals for therapies in Parkinson’s disease, autism spectrum disorder, C3G, IC-MPGN, and paroxysmal nocturnal hemoglobinuria (PNH)
- 60% repeat sponsor rate
- Studies conducted in 48 countries, reaching 65% of the global population